Other substances

(5S,5Ar,8aR,9S)-5-[[(2S,4aR,6R,7S,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,[2]benzofuro[6,5-f][1,3]benzodioxol-8-one

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

(5S,5Ar,8aR,9S)-5-[[(2S,4aR,6R,7S,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,[2]benzofuro[6,5-f][1,3]benzodioxol-8-one on PubChem

Synonyms

ZINC3830817; ZINC03830817

Marketed as

DEVOTAN; FORDIAB; GLIDIAB; GLUNORMAL; GLURENOR; GLURENORM; JIE SHI; KA RUI LIN; LODEM

 

Structure image - (5S,5Ar,8aR,9S)-5-[[(2S,4aR,6R,7S,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,[2]benzofuro[6,5-f][1,3]benzodioxol-8-one

C[C@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor
3CLpro Small molecule In silico 		in silico 3.22

Predicted to bind the SARS-CoV-2 3C-like protease.

 Sep/17/2020
Export (.csv)